Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Hyperbaric oxygen therapy for the treatment of long COVID

Peter Wilmshurst, Susan Bewley and Patricia Murray
Download PDF
DOI: https://doi.org/10.7861/clinmed.Let.23.1.2
Clin Med January 2023
Peter Wilmshurst
Royal Stoke University Hospital, UK
Roles: Consultant cardiologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Bewley
King's College London, UK, and trustee of HealthSense-UK
Roles: Emeritus professor of obstetrics and women's health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Murray
University of Liverpool, UK
Roles: Professor of stem cell biology and regenerative medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Editor – We raise concerns about the article by Robbins et al describing hyperbaric oxygen therapy (HBOT) for the treatment of long COVID.1

The NHS commissions HBOT for treatment of decompression sickness and gas embolism at 11 facilities. The use of HBOT for these diseases has both evidence of efficacy and a plausible mechanism of action: increased ambient pressure compresses the free gas in the patient (according to Boyle's Law) and causes it to dissolve in tissues (according to Henry's Law), while breathing 100% oxygen creates a gradient for elimination of inert gas (usually nitrogen).

A number of other hyperbaric facilities offer private HBOT for treatment of diseases for which there is neither evidence of efficacy nor a plausible hypothesis for a therapeutic mechanism. These include Alzheimer's disease, autism, cancers, depression, HIV/AIDS, Lyme disease and Parkinson's disease. Some facilities provide HBOT for multiple sclerosis although 12 randomised trials have identified no clinically significant benefit.2

This report states that 10 patients received 10 sessions of HBOT at 2.4 atmospheres. Only one author, who works at the Midlands Diving Chamber, treated the patients and he performed the pre- and post-treatment assessments of fatigue and cognitive scoring. The remaining 10 authors, who work at the University Hospitals Coventry and Warwickshire NHS Trust, analysed the data (which we estimate should have taken one person one day). The article reports that HBOT yielded significant improvements in fatigue scale, global cognition, executive function, attention, information processing and verbal function. The authors conclude that the results suggest potential benefits of HBOT in the treatment of long COVID.

We believe it is unacceptable that this experimental non-comparative efficacy trial had ethics approval only for the data analysis. It did not have ethics approval for the exposure of patients to the unproven use of HBOT in a clinical trial. If the patients were not told that they were participating in a research clinical trial, they did not give adequately informed consent.

HBOT involves risks of barotrauma to lungs and ears, and oxygen-induced pulmonary pneumonitis and neurological toxicity. The latter causes convulsions with the risk of aspiration for patients wearing a face mask or hood in the hyperbaric chamber.

The trial was not blinded for either patients or the treating doctor, who performed the assessment in the private facility. Whether the research was funded by the subjects paying for ‘private treatment’ is not stated.

Placebo effects are likely as HBOT facilities are highly technical. Patients are locked in a hyperbaric chamber and usually wear a mask or hood. They experience pressure sensations in their ears and temperature alterations as ambient pressure in the chamber changes.

The Midlands Diving Chamber now cites this paper on its website as evidence of efficacy of HBOT in long COVID to attract paying customers.3

We believe that Clinical Medicine should publish an expression of concern about this paper whilst the journal investigates whether there was ethical approval for the actual research and not just the analysis. If there was not, the article should be retracted.

Note from the editor

The authors have confirmed that they obtained ethical approval for this retrospective analysis from the University Hospitals Coventry & Warwickshire NHS Trust R&D Committee. The authors make clear in their paper that their findings represent only an initial evaluation with a very small sample and that further study is essential.

  • © Royal College of Physicians 2023. All rights reserved.

References

  1. ↵
    1. Robbins T
    , Gonevski M, Clark C, et al. Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med 2021;21;e629–32.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Bennett M
    , Heard R. Hyperbaric oxygen therapy for multiple sclerosis. Neuroscience Therapeutics 2010;16:115–24.
    OpenUrl
  3. ↵
    https://oxygenhealing.co.uk/news/hyperbaric-oxygen-therapy-for-the-treatment-of-longcovid-early-evaluation-of-a-highly-promising-intervention/ [Accessed 23 November 2022].
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Hyperbaric oxygen therapy for the treatment of long COVID
Peter Wilmshurst, Susan Bewley, Patricia Murray
Clinical Medicine Jan 2023, 23 (1) 99-100; DOI: 10.7861/clinmed.Let.23.1.2

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Hyperbaric oxygen therapy for the treatment of long COVID
Peter Wilmshurst, Susan Bewley, Patricia Murray
Clinical Medicine Jan 2023, 23 (1) 99-100; DOI: 10.7861/clinmed.Let.23.1.2
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Note from the editor
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Letters to the Editor
  • Letters to the Editor
  • Letters to the Editor
Show more Letters to the editor

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians